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Hypercholesterolemia is the most common coronary risk factor among the Spanish population; 
37.4% of the Spanish adult population have cholesterol levels between 190 and 240 mg/dl. 
Foods enriched with plant sterols (PS) can effectively reduce plasma cholesterol in patients with 
high levels. However, its effectiveness and safety in adults with moderate hypercholesterolemia 
who are on medication (statins) or not has been less studied. The aim of this review is to 
establish the possible role of plant sterols in the control of hypercholesterolemia, as well as 
how safe they are for people with moderate hypercholesterolemia treated with statins. The 
main studies were looked at, regardless of design, language or publication date which studied 
the connection between “plant sterols” and “hypercholesterolemia”, using Pubmed/Medline, 
SCOPUS and Google Scholar databases. The studies brought together in this review show that 
an intake of between 2 and 3g/day of plant sterols effectively reduces plasma cholesterol 
levels in patients with hypercholesterolemia. Both clinical studies and available meta-analyses 
do not indicate any problems related to the drug-nutrient interaction associated with the use 
of plant sterol-enriched foods. In patients with moderate hypercholesterolemia where the use 
of statins is not justified a healthy diet, exercise and foods high in PS can provide the best 
therapeutic approach.
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 La hipercolesterolemia es el factor de riesgo cardiovascular más frecuente en la población es-
pañola. El 37,4% de la población adulta española presenta niveles de colesterol de entre 190 y 
240 mg/dl. Los alimentos enriquecidos con esteroles vegetales (EV) pueden disminuir de forma 
efectiva el colesterol plasmático en pacientes con niveles elevados, sin embargo su efecto y se-
guridad en adultos con hipercolesterolemia moderada, tratados o no con fármacos (estatinas) 
ha sido menos estudiada. El objetivo de la presente revisión es establecer el posible papel de los 
esteroles vegetales en el control de la hipercolesterolemia, así como su seguridad en personas 
con hipercolesterolemia moderada tratada con estatinas. Se revisaron los principales estudios, 
sin limitación de diseño, lengua o fecha de publicación que relacionara “esteroles vegetales” 
e “hipercolesterolemia”, explotando las bases de datos Pubmed/Medline, SCOPUS y Google 
Scholar. Los estudios recuperados en la presente revisión muestran que el aporte de entre 2 y 
3g/día de esteroles vegetales disminuyen de forma efectiva los niveles de colesterol plasmático 
en pacientes con hipercolesterolemia. Tanto los estudios clínicos como los metaanálisis disponi-
bles no muestran problemas relacionados con la interacción fármaco-nutriente asociada al uso 
de alimentos enriquecidos con EV. En pacientes con hipercolesterolemia moderada en que no 
esté justificado el uso de estatinas, una alimentación saludable, actividad física y alimentos con 
EV, puede constituir el mejor acercamiento terapéutico.
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INTRODUCTION
Hypercholesterolemia is a metabolic imbalance characterised 
by the presence of high levels of cholesterol in the blood. In 
general hypercholesterolemia is diagnosed when cholesterol 
values are equal to or above 240 mg/dl1,2, although there 
is no universally accepted criteria to define this disorder3,4. 
In this respect there are entities who differentiate between 
primary prevention (patients who have not clinically 
shown ischemic vascular disease) and secondary (patients 
who have clinically shown ischemic vascular disease). The 
Catalan Health Institute, for instance, considers that 
hypercholesterolemia exists when the total cholesterol is 
equal to or over 200 mg/dl in primary prevention, while 
in secondary prevention hypercholesterolemia is defined 
when values of cholesterol linked to low density proteins 
(cLDL) are equal to or above 100 mg/dl5. In any case, there 
is no definite cut-off point between normal and abnormal 
cholesterol levels and this is why doctors interpret patients’ 
readings in relation to other health conditions and risk 
factors of coronary heart disease. 
It is well established that high total cholesterol and LDL 
cholesterol is associated with a clearly increased risk in 
developing coronary heart disease6. In fact, high levels of 
cholesterol are one of the main factors of coronary heart 
disease7 to the extent that high cholesterol increases the 
risk of ischemic heart disease in an independent, severe 
and continual way3,8,9. This can be observed even among 
populations with low coronary heart disease risk3,10. 
Moreover, the association between cholesterol levels and 
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Plant sterols (also called phytosterols), are organic 
compounds from the plant kingdom which have a structure 
and cell function equivalent to that of cholesterol in 
vertebrates13–15. This similarity is of paramount importance 
when it comes to justifying their role in the control of 
cholesterol in humans as this means that both dietary 
and bile cholesterol compete with the plant sterols in 
the intestine to be absorbed. In this way the plant sterols 
reduce the amount of cholesterol that enters the blood 
stream. Furthermore, the absorption rate of plant sterols in 
humans is very low, something which does not happen with 
cholesterol. These reasons explain why plant sterols reduce 
cholesterol in humans13,16–19.
Oils, cereals, pulses, fruit and vegetables are the main dietary 
sources of plant sterols in the Spanish diet. It is estimated 
that they provide an average of 276 mg/day20. Nevertheless, 
this figure does not show significant reductions in cholesterol 
levels. In this sense functional foods enriched with plant 
sterols are designed to provide between 1 and 3 g/day of 
these substances, a figure which is between 2 to 10 times 
higher than that which is usually achieved through diet21.
Several rigorous studies conclude that foods enriched with 
plant sterols may effectively reduce plasma cholesterol in 
patients with hypercholesterolemia22–25. The National Heart, 
Lung and Blood Institute of the United States considers 
that foods enriched with plant sterols reduce levels of 
LDL cholesterol between 6–15%26. Current American 
guidelines on the management of cholesterol in adults 
include recommendations about ingesting ~2 g/day of 
plant sterols in order to reduce total cholesterol in patients 
with hypercholesterolemia6. The European Food Safety 
Authority (EFSA), associated to the European Commission 
and the European Parliament, and whose advisory council 
is represented by the Spanish Food and Nutrition Safety 
Agency in Spain (AESAN), considers there to be a cause-
effect relationship (in the form of dose-dependency) 
between the intake of foods enriched with plant sterols 
and the reduction in LDL cholesterol27–30. More recently, in 
2011, the American Diabetes Association recommended 
all patients with diabetes to increase their intake of plant 
sterols in order to improve their lipid profile31. One year later 
European guidelines32,33 on the prevention of cardiovascular 
disease pointed out that functional foods containing plant 
sterols are effective in reducing LDL cholesterol. Two meta-
analysis published in 2011 and 2014, also indicated that 
these foods do so by approximately 6–12% when taken in a 
PLANT STEROLS AND    
HYPERCHOLESTEROLEMIA
ischemic disease is not only lineal but it can begin to be 
visible in values of 150 mg/dl5.
Hypercholesterolemia is the most common cardiovascular 
risk factor among the Spanish population. Between 17–50% 
(depending on the cut-off point used) of Spanish people 
suffer from hypercholesterolemia1,3,4. It is estimated that 
hypercholesterolemia is the cause of one fifth of coronary 
events in Spain, where coronary heart disease is the first 
cause of hospitalisation and death. In 2008 it was the cause 
of over 122,000 deaths and over 5 million hospital stays1.
According to statistics from the ENRICA study, 37.4% 
of the Spanish adult population have cholesterol levels 
between 190 and 240 mg/dl. Applying this prevalence 
among the Spanish population of 18 years of age and older, 
approximately 14.5 million Spanish men and women have 
cholesterol levels within this range3.
The only research that has been found to evaluate the 
approximate number of Spanish people with moderate 
hypercholesterolemia and who are also being treated 
with statins was a cross sectional study which included 
804 patients aged between 35–74, randomly selected 
from two Spanish health centres. According to this study, 
approximately 9.5% of patients without high cardiovascular 
risk were treated with statins11. Although the extrapolation 
of results in other populations should be conducted with 
caution, given that this is not a strict multicentre study, if 
these statistics were confirmed for the rest of the Spanish 
adult population, they may generate the hypothesis that 
about 1.4 million Spanish adults are unjustifiably being 
treated with statins. 
In this respect, the French High Authority of Health 
observes a certain abuse in the prescription of statins 
in primary prevention in France12. No data has been 
found on the number of Spanish people with moderate 
hypercholesterolemia who habitually ingest foods enriched 
with plant sterols. The aim of this review is to establish what 
is known about the role of plant sterols in the control of 
hypercholesterolemia, and to find out if there are studies 
which evaluate the safety of the use of plant sterols, 
especially in people with hypercholesterolemia who are 
on medication. The main studies were reviewed without 
limitations of design, language or publication date which 
linked “plant sterols” and “hypercholesterolemia”, using 
the databases of Pubmed/Medline, SCOPUS and Google 
Scholar.
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The intake of plant sterols is accompanied by slight increases 
in plasma concentrations of plant sterols, and certain 
studies have suggested that this increase could increase the 
risk of coronary heart disease39. However, a study carried out 
among the Spanish population within the framework of the 
EPIC study showed that plasma levels of sitosterol, the main 
plant sterol in the diet, was associated with a lower risk of 
coronary heart disease40. In any case, a recent meta-analysis 
(2012) concluded that this increase would not be relevant 
for coronary heart disease risk41.
The Scientific Committee on Food of the European 
Commission considers that people with inherited metabolic 
disorders must be aware of the presence of high levels of 
phytosterols in foods enriched with plant sterols42. In any 
case, despite the fact that the intake of plant sterols is not 
recommended for people who suffer from homozygous 
sitosterolemia, a recent study has shown that in heterozygous 
sitosterolemia the intake of plant sterols would be safe43. 
In any event, the prevalence of this pathology is very low 
among the population in general.
The European Commission considers that the use of 
foods enriched with plant sterols, in compliance with the 
information in Table 1 is safe, although an intake of plant 
sterols above 3 g/day is not recommended42,44,45.
Statins are the first choice of medication in the treatment of 
hypercholesterolemia, due to their proven efficacy based on 
scientific evidence46–49. Nevertheless, it should be specified, 
DRUGS OR COMBINATIONS OF DRUGS 
AND HYPERCHOLESTEROLEMIA 
dose of 2–3 g/day34,35. It indicated that their effectiveness is 
added to that provided by statins32,33.
POSSIBLE SIDE EFFECTS    
OF PLANT STEROLS
In spite of the possible effect of plant sterols on the absorption 
or metabolism of certain nutrients, in particular liposoluble 
ones21, the evidence available shows that plant sterols have 
no significant effect on the absorption and metabolism of 
vitamins A, D, E, alpha-carotene or lycopene26. There are 
doubts, however, about a possible interference from plant 
sterols on the absorption of beta-carotenes. The scientific 
literature includes tests which indicate that levels of beta-
carotenes may be slightly reduced, although it would seem 
that this would not produce any side effects26. In any case, it 
is recommended that the continual intake of foods enriched 
with plant sterols is accompanied by a diet high in fruit and 
vegetables which are high in beta-carotene and liposoluble 
vitamins, or that these nutrients are added to foods that 
contain plant sterols6.
Gupta et al. (International Centre for Circulatory Health, 
National Heart & Lung Institute, Imperial College London) 
point out that both clinical tests and available meta-analyses 
do not indicate any problems related to the drug-nutrient 
interaction associated with the use of foods enriched with 
plant sterols36. Likewise, Mailonwski and Gehret consider 
that plant sterols in the doses recommended in enriched 
foods have little interaction with drugs37. Available clinical 
tests (and meta-analyses) have not indicated any important 
safety issues (side effects)36. A recent study has confirmed, 
moreover, the stability of plant sterols in functional foods38.
Table 1. Conditions for use in the EU of health declaration approved for plant sterols62–64.
Conditions for use in the EU health declaration approved for plan sterols.
Information to the consumer that the beneficial effect is obtained with a daily intake of 1.5-2.4 g of 
plant sterols/stanols. 
Reference to the magnitude of the effect of yellow fat spreads, dairy products and salad dressings, 
mayonnaise enriched with plant sterols.
When referring to the magnitude of the effect, the reduction in cholesterol will range between 7 and 
10%, and the duration to obtain the effect of 2-3 weeks must be communicated to the consumer.
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quality in using statins in primary prevention in patients 
with low risk of coronary heart disease is limited. Cochrane 
therefore recommends precaution when prescribing these 
drugs in primary prevention for patients with low risk of 
coronary heart disease51. It should not be overlooked that 
the prescription of statins has undergone an important 
increase in recent years. The efficacy of statins in primary 
prevention in women and people over 65 has not been well 
established11.
Although statins are well tolerated as a whole, and serious 
side effects are rarely reported, their widespread use 
magnifies these events. Among the risks of unjustified 
use of statins type 2 diabetes stands out (a risk which is 
compensated if the medication is justified, by the reduction 
of coronary heart disease), myopathy (especially in people 
with complex medical conditions and/or who are prescribed 
a lot of medication, or in the elderly), myalgia (between 
5–10%), elevated transaminases and drug interactions. 
Moreover, an inter-individual variation in response to statin 
therapy has been observed, as well as the incidence of side 
effects50,56. In any case, as the European Association for 
Cardiovascular Prevention and Rehabilitation points out, the 
clinical conditions of the patients, concomitant treatments 
and tolerance to the drug will play an important role in 
determining the final choice of drug and dosage50. Patients 
should not discontinue treatment without first consulting 
their doctor if they are concerned about this and should ask 
their doctor at their next appointment.
Top organisations recommend that in low risk patients the 
use of statins should not be considered as the first option 
and that these patients should opt for a healthy diet and 
plant sterols before starting treatment with prescribed 
drugs6,57.
CONCLUSIONS
Taking into account the abovementioned data, there would 
appear to be a clear consensus which justifies the usage of 
plant sterols in lowering the risk of coronary heart disease 
in patients with hypercholesterolemia, where this usage 
has few side effects and where rigorous studies show 
that prescribing statins for primary prevention for low 
risk coronary heart disease patients should be done with 
caution51,56.
Consequently, it is to be considered that a balanced diet 
together with functional foods with sufficient amounts 
of plant sterols is the most recommendable way to treat 
hypercholesterolemia in patients with measurements 
as the European Association of Cardiovascular Prevention 
and Rehabilitation points out, that there are other drugs or 
combinations of drugs which the doctor may evaluate when 
treating this disease. Therefore, in the case of intolerance to 
statins, a first option should be to consider prescribing bile 
acid sequestrants or nicotinic acid. 
As a second option the use of cholesterol absorption 
inhibitors should be evaluated, either on their own or in 
combination with bile acid sequestrants and nicotinic acid. 
However, if treatment with statins does not have the desired 
effect as stipulated by the doctor in relation to cholesterol 
readings, a prescription of a combination of statins with a 
cholesterol absorption inhibitor or a bile acid or nicotinic 
acid sequestrant is recommended50.
Statins and/or plant sterols for patients with 
hypercholesterolemia and high risk of heart disease
It is well established that patients with hypercholesterolemia 
and a high risk of coronary heart disease benefit, in terms 
of reducing mortality, from the first choice drug: statins51. 
Nevertheless, most patients with a high risk of coronary 
heart disease who are treated with statins in Spain fail to 
achieve the recommended lipid targets52.
With respect to the combination of hypocholesterolemic 
medication (statins) with foods enriched with statins, far 
from being harmful, they are in fact beneficial in the control 
of plasma cholesterol22,26,53, as is recognised by the European 
Society of Cardiology32,33. This fact has been confirmed by a 
recent meta-analysis carried out by Scholle JM et al.54. In any 
case The European Authority on Food Safety has indicated 
that people with high cholesterol and who are already 
taking medication for their cholesterol should only consume 
foods enriched with statins under medical supervision28,29.
Statins and/or plant sterols for patients with moderate 
hypercholesterolemia 
Although statins are justified in patients with 
hypercholesterolemia and high coronary heart disease risk, 
as far as primary prevention is concerned (patients who have 
not clinically shown any ischemic vascular disease) there 
are doubts about the risk-benefit balance of using these 
drugs. The French High Authority of Health points out that 
statins should be reserved for patients who are at high risk, 
that is, who combine several risk factors such as diabetes, 
hypertension, smoking, etc.12. These ideas are shared by the 
American Heart Association55 and the American Diabetes 
Association31.
Similarly, a meta-analysis carried out by Cochrane et al. 
in 2011 showed that evidence of benefits in terms of life 
Rev Esp Nutr Hum Diet. 2015; 19(2): 105 - 115
110 Plant sterols for adults with hypercholesterolemia treated with or without medication (statins)
theoretical figure of 1.4 million Spanish adults could see 
a reduction in plasma cholesterol readings. A simulation 
carried out in the United Kingdom showed that the daily 
intake of foods enriched with plant sterols represented 
an 11.8% reduction in coronary events. Its conclusion was 
that a “universal” therapy using these foods could lead to 
a very significant decrease in coronary disease rates59. It is 
important to note that the European Society of Cardiology 
has recently indicated that the positive effect on the 
reduction of coronary risk that is noted after the decrease 
in cholesterol levels is independent of the method used to 
achieve this reduction (drugs, plant sterols, diet or changes 
in lifestyle)32,33.
Both the European Society of Cardiology32,33, as well as data 
from well-designed studies60 confirm that the combination 
of the intake of foods enriched with plant sterols together 
with a healthy diet has a synergic effect.
The European Union Register on nutrition and health61 
points out that the authorised declaration of health within 
the framework of the European Community associated 
with foods enriched with plant sterols is the following: 
“Plant sterols and plant stanol esters have been proven to reduce 
cholesterol in the blood. High cholesterol is a risk factor in the 
development of heart disease”. The conditions of use of this 
health declaration are stated in Table 162–64.
New scientific advice on plant sterols points out that as well 
as previously approved health statements, there is sufficient 
evidence to conclude that the intake of 3 g daily of plant 
sterols or plant stanols (range 2.6–3.4 g/day) in the matrices 
approved by Regulation (EC) nº 376/2010 (yellow fat 
spreads, dairy products, mayonnaise and salad dressings)63, 
lowers LDL cholesterol by 11.3%. The minimum length of 
between 190 and 240 mg/dl, except where clinical 
judgement is to the contrary.
Health professionals can feel confident when prescribing 
foods enriched with plant sterols for the treatment of 
moderate hypercholesterolemia (except, as has been 
mentioned, where clinical judgement is to the contrary)58.
In this way, it is expected that each reduction of 1 mg/dL in 
LDL serum cholesterol can correspond to a 1% reduction in 
the risk of developing heart disease57. The abovementioned 
meta-analysis show that plant sterols in doses of 1–3 g/day 
can reduce LDL cholesterol by between 12 and 24 mg/dL23-25, 
which would represent a reduction of 12–24% in the risk 
of heart disease. It is without a doubt a clinically relevant 
benefit. One meta-analysis showed that the addition of 2 g 
of plant sterols to a daily portion of margarine can produce 
a reduction in LDL cholesterol which would mean up to a 
25% reduction in the risk of coronary heart disease. This is 
a better than expected effect for people who reduce their 
intake of saturated fats22. 
The European Society of Cardiology has recently indicated 
that the daily intake of functional foods containing about 2 g of 
plant sterols reduces cholesterol readings by 10%32,33. Foods 
enriched with plant sterols may therefore play an important 
role in the protection against atherosclerosis and coronary 
heart disease in patients with hypercholesterolemia28,29.
Likewise, it is expected that the intake of plant sterols by 
people with moderate hypercholesterolemia who take 
statins reduces potential side effects. It is also expected 
that a large number of Spanish people can benefit from 
this recommendation with respect to the reduction in the 
risk of coronary heart disease. As was previously stated, a 
Table 2. Interventions for reducing cholesterol levels and expected degree of efficacy that they produce, according to the 
European Association for Cardiovascular Prevention and Rehabilitation50.
Intervention
Reduce intake of saturated fats
Reduce intake of trans fatty acids
Use functional foods enriched with plant sterols 
Increase intake of foods rich in dietary fibre
Reduce intake of dietary cholesterol
Reduce excess body weight
Increase regular exercise
Degree of efficacy
+++
++
+
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intervention should improve diet, encourage exercise, 
weight loss (where necessary) and the giving up of smoking. 
Nutritional intervention should be adapted to suit each 
patient, their age and other medical conditions as well as 
the information set out in Table 2. It is important to point 
out that the reduction in the intake of foods rich in saturated 
fats together with an intake of foods enriched with plant 
sterols may reduce LDL by as much as 20%26. Tables 2–4 sum 
up food and nutrition advice and lifestyle recommendations 
from the authors.
time necessary in order to achieve the maximum effect of 
plant sterols and stanols in the reduction of cholesterol 
would be from two to three weeks65.
Therefore, it is considered that the treatment with foods 
containing plant sterols should include a daily minimum 
of 1.5 g and a maximum of 3 g/day. Continual monitoring 
and counselling are crucial as this kind of therapy is only 
effective if it is properly followed58,66.
A change in lifestyle is one of the keys to success in all 
treatments that aim to reduce blood lipids. Nutritional 
Table 3. Dietary recommendations for lowering cholesterol, adapted from the European Association for Cardiovascular 
Prevention & Rehabilitation, 201150.
Dietary recommendations for reducing  cholesterol
Preferable
Whole grain
Raw or cooked  
vegetables
All
Fresh or frozen
Calorie-free sweeteners
White and oily fish, 
skinless free-range poultry
Skimmed milk, low-fat 
yoghurts, egg white
Vegetable oils, vinegar, 
ketchup, mustard, fat-free 
dressings, margarines 
containing plant sterols†
Stews, boiled, steamed
Cereals
Vegetables
Pulses
Fruit
Sugars and sweeteners
Meat and fish
Dairy products  and eggs
Cooking oils and dressings
Dried fruit and nuts/seeds
Cooking procedures 
To be consumed in  
moderation
Refined grains or derivatives: 
bread, rice, pasta or 
processed breakfast cereal
Dried, preserved, jams and 
marmalades, sorbets, in 
syrup, etc.
Saccharine, honey, fructose, 
glucose, chocolate, sweets
Lean cuts of beef, lamb, pork, 
seafood
Semi-skimmed milk, low-fat 
cheese or other dairy products
Soft margarines, salad 
dressings, mayonnaise
All
Stir-fried, roasted
To be consumed occasionally 
and in small amounts
Pastries, croissants, etc.
Vegetables prepared with 
creams or butter
Cakes and ice-creams
Sausages, salami, bacon, 
hotdogs, offal
Cheese, cream, egg yolk, full-
cream milk and yoghurt
Butter, hard, margarines*, 
coconut and palm oil, lard, 
dressings containing egg 
yolk
Coconut
Fried
† In adults con hypercholesterolemia. Intake in patients who are on take hypocholesterolemic medication, children, pregnant and 
breastfeeding women should only do so under medical supervision; *Not commercially available in Spain.
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Table 4. Summary of measures related to lifestyle and healthy diet in order to reduce coronary heart risk, adapted from 
the European Association for Cardiovascular Prevention & Rehabilitation50.
Summary of measures related to lifestyle and healthy diet choices for reducing coronary heart disease risk
Dietary recommendations should take into account local habits, although interest should be promoted in 
healthy diets from other cultures.
A healthy diet should be based on a varied intake of foods of mainly plant origin. 
The calorific intake should be adjusted to prevent excess weight and obesity.
Intake of saturated fat should be reduced and should not surpass 7% of the daily calorific intake. Dietary cho-
lesterol should not be above 300 mg/day. Limiting intake of red meat, cold meats and processed meat as well 
as full-fat dairy products will help to achieve this goal.
Salt intake should be less than 5 g/day. Not placing the salt cellar on the dining table, adding less during coo-
king and especially reducing the intake of cold meats, cheese and bread containing salt as well as ready-made 
meals will help to reach this target. 
If you suffer from hypertriglyceridemia you should avoid drinking alcoholic beverages. For the rest of the adult 
population the message from the World Health Organisation in this respect is the most adequate: “the less 
alcohol, the better”.
The intake of drinks and foods with added sugar should be limited, especially soft drinks.
A minimum of 30 minutes physical exercise should be done a day. 
The use of and exposure to tobacco should be avoided.
of Spain, 2008-2010: The ENRICA Study. Rev Esp Cardiol (Engl 
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